Study the pathological features of diseases using induced pluripotent stem cells derived form patient's somatic cells
The limited experimental access to disease-affected human tissues has severely impeded the elucidating of molecular mechanisms underlying disease development. Generation of induced pluripotent stem cells (iPSCs) by over-expression of defined transcription factors in somatic cells, in particular in those from patient somatic cells, presents an attractive and promising approach to model the early stages of diseases in vitro and to screen novel biomarkers as well as therapeutic medicines. Recently, many research groups have independently reported that patient-specific iPSC-derived cells recapitulated multiple features of pathological events of a particular disease, offering experimental evidence of utilizing patient-specific iPSCs to model diseases and reevaluate the current therapies. We have derived iPSC lines using somatic cells of patients suffering from Klinefelter's Syndrome (KS) and Alzheimer's Disease (AD) and explored the possibility to use these iPSC lines to recapitulate the pathological features of the diseases. Our results show that patient's specific iPSC lines provide good opportunity to study the development and treatment of diseases.
sRNA Induces the Large-scale Transdetermination of Mesenchymal Stem Cells into Hematopoietic Stem Cells in Human.
Mesenchymal stem cells (MSCs) can differentiate into cells of bone, endothelium, adipose tissue, cartilage, muscle, and brain. However, whether they can transdeterminate into hematopoietic stem cells (HSCs) remains unsolved. We report here that a subpopulation of human MSCs that are CD44+,CD29+, CD105+, CD166+,CD133-,CD34- could differentiate into hematopoietic stem cells (CD150+/CD133+/CD34+) and their descending blood cells in vitro, when transfected with new endogenous shRNAs The sRNA was high-effectively delivered into MSCs by a novel peptide means. These induced MSC-HSCs could form different types of hematopoietic colonies as nature-occurring HSCs did. Upon transplantation into sublethally irradiated NOD/SCID mice, these MSC-HSCs engrafted and differentiated into all hematopoietic lineages such as erythrocytes, lymphocytes, myelocytes and thrombocyte. More importantly, these induced HSCs could successfully engraft and effectively function in patients with severe aplastic anemia. Furthermore, we demonstrated the first evidence that the transdetermination of MSCs was induced by acetylation of histone proteins and activation of many transcriptional factors. Together, our findings identify the sRNAs that dictates a directed differentiation of MSCs toward HSCs and open up a new source for HSCs used for the treatment of blood diseases and artificial stem cell-made blood.
immunotherapy against cancers(position of sellular therapy)
Study the pathological features of diseases using induced pluripotent stem cells derived form patient's somatic cells
The limited experimental access to disease-affected human tissues has severely impeded the elucidating of molecular mechanisms underlying disease development. Generation of induced pluripotent stem cells (iPSCs) by over-expression of defined transcription factors in somatic cells, in particular in those from patient somatic cells, presents an attractive and promising approach to model the early stages of diseases in vitro and to screen novel biomarkers as well as therapeutic medicines. Recently, many research groups have independently reported that patient-specific iPSC-derived cells recapitulated multiple features of pathological events of a particular disease, offering experimental evidence of utilizing patient-specific iPSCs to model diseases and reevaluate the current therapies. We have derived iPSC lines using somatic cells of patients suffering from Klinefelter's Syndrome (KS) and Alzheimer's Disease (AD) and explored the possibility to use these iPSC lines to recapitulate the pathological features of the diseases. Our results show that patient's specific iPSC lines provide good opportunity to study the development and treatment of diseases.
New Trends in RNA-seq
来自Illumina China的测序产品经理余菽亮，分别从以下几个方面做了详细介绍： 在RNA序列的新的趋势，RNA序列的好处，RNA序列的挑战RNA序列的进化，Truseq Standed RNA dUTP method ，提供完整的rRNA转录覆盖更多还原，Truseq @ RNA库准备概述，单细胞测序的方法个别肿瘤细胞的转录组分析，细胞类型特异性基因表达标记，Fluidigm单细胞自准备系统概述等。
Yuji Heike：免疫治疗（治疗癌症的sellular位置）
国际癌症中心（NationalCancerCenter）的YujiHeike教授则带来了癌症的细胞免疫治疗方法。他认为今后组合疗法是癌症治疗的主流方法，并对癌症免疫疗法进行了详细介绍。以PD-1在肺癌中的免疫疗法为案例进行了详细阐述。最后他还号召全亚洲能够加入ACTO，共同合作研究。
small RNA-seq - 陈巍学基因（9）
本期课程介绍：
1、small RNA建库测序的方法；
2、small RNA测序数据的生物信息学分析（A、表达量差异分析；B、聚类分析；C、GO分析；D、KEGG Pathway分析）；
3、血清和血浆micro RNA测序的意义、和样本准备
Hiseq测序仪工作原理 - 陈巍学基因（2）
Illumina Hiseq 2500是精密的显微光学仪器，结合液流、温控、数据处理等一系列系统，输出海量的测序数据。
本课程介绍了其光学结构、扫描方式、图像处理、数据判读、和数据输出方面的知识。
RNA-seq方法和应用- 陈巍学基因（7）
NA-seq是高通量测序中最常见的一种应用。
本期课程介绍其：
1、方法原理；
2、生物信息分析，表达差异、火山图展示、聚类分析、GO、Pathway、可变剪接、融合基因、点突变
Alan Russell:讲人体的再生
Alan Russell研究的是再生医学 - 以一种突破性的思维方式去看待疾病与损伤，以一种方式向人体发送信号诱导其进行自我修复。